Joana Carvalho, PhD,  managing science editor—

Tudorza (aclidinium bromide) reduces flare-ups in patients with moderate to severe chronic obstructive pulmonary disease (COPD) without increasing the risk of cardiovascular complications such as heart attack and stroke, or death, data from a Phase 4 trial show. The findings were discussed by Robert Wise, MD,…

The use of electronic cigarettes, more commonly known as vaping, triggers cellular responses in the lungs similar to those elicited by smoking tobacco cigarettes, which may place e-cigarette users at risk of developing chronic lung diseases, a study says. Results from the study, “Chronic E-Cigarette Use Increases Neutrophil Elastase…

Patients with chronic obstructive pulmonary disease (COPD) who are experiencing severe exacerbations should receive noninvasive ventilation, regardless of factors such as older age, low body mass index (BMI), left heart dysfunction, and abnormal levels of gases in the blood, a study suggests. Researchers in the study found that these…

Nuvaira, a medical device company, announced the upcoming publication of several scientific studies detailing the findings of clinical trials that assessed the safety and effectiveness of its Targeted Lung Denervation (TLD) therapy in patients with chronic obstructive pulmonary disease (COPD). Nuvaira’s proprietary TLD therapy works to disrupt pulmonary…

Olympus‘ Spiration Valve System (SVS), a device that can be inserted into a patient’s airways to redirect air from diseased regions of the lungs and toward its healthier parts, improves respiration in people with severe emphysema, a clinical trial found. Its results were reported in the study, “…

Patients with chronic obstructive pulmonary disease (COPD) are more susceptible to bone fractures and osteoporosis than those of the same age and sex without this disease, a study reports. The findings were published in the journal BMJ Open, in the article “Predicting fracture risk in patients with chronic…

CSA Medical‘s RejuvenAir System received the designation of Breakthrough Device by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic obstructive pulmonary disease (COPD). The FDA also gave the company an unconditional Investigational Device Exemption (IDE) approval to test the system in…

The U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application for the addition of new clinical data on on the label of Tudorza (aclidinium bromide), a bronchodilator for the long-term treatment of chronic obstructive pulmonary disease (COPD) marketed by Circassia Pharmaceuticals…

The U.S. Food and Drug Administration (FDA) approved a new label for Stiolto Respimat (a combination therapy of tiotropium bromide and olodaterol) based on data from clinical trials showing a significant reduction in the frequency of chronic obstructive pulmonary disease (COPD) exacerbations driven by tiotropium, the active ingredient of …

Hospitalized patients with chronic obstructive pulmonary disease (COPD) who also suffer from atrial fibrillation (AFib), a condition where the heart beats faster, have a greater risk of developing liver disease and respiratory failure compared to those not affected by AFib, according to researchers. Their study, “…